Skip to main content

Table 1 Clinicopathological features of OS patients evaluated for YAP expression by immunohistochemistry (IHC) in 175 tissue samples

From: ROCK2 deprivation leads to the inhibition of tumor growth and metastatic potential in osteosarcoma cells through the modulation of YAP activity

Characteristics N % Association with prognosis (RFS)a Association with survival (OVS)b
Gender    P = 0.67 P = 0.92
 Female 72 41.1   
 Male 103 58.9   
Age    P = 0.37 P = 0.10
 ≤ 14 years 82 46.9   
 > 14 years 93 53.1   
Surgery    P = 0.47 P = 0.91
 Resection 158 90.3   
 Amputation 12 6.9   
 Rotation plastic 5 2.8   
Margins    P = 0.10 P = 0.36
 Adequate 147 84.0   
 Inadequate 28 16.0   
Chemotherapy response (Necrosis)    P = 0.05 P = 0.21
 Good 105 60.0   
 Poor 69 39.4   
 NA 1 0.6   
RFS (status)     
 NED 90 51.4   
 REL 85 48.6   
OVS (status)     
 Living 122 69.7   
 Dead 53 30.3   
  1. Associations with prognosis were calculated by univariate analysis using the log-rank test
  2. OS osteosarcoma, NED no evidence of disease, REL relapsed, RFS relapse-free survival, OVS overall survival
  3. aRFS (median follow-up: 95 months; range 2–415 months)
  4. bOVS (median follow-up: 156 months; range 7–415 months)